English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Within a wider research project aimed at the pre-industrial development of nanotechnology platforms for the treatment of eye diseases, this work exploited the possibility of obtaining solid lipid nanocarriers (SLN) using ingredients and operating conditions that could be compatible with the technological requirements of medical formulations used for ophthalmic therapies and, above all, capable of an easy industrial scale-up. In particular, we tested the possibility of adapting a production method known as Quasi-emulsion Solvent Diffusion (QESD), which already shows a number of operational advantages, such as use of low temperatures and reduced concentrations of surfactants, also to very small production volumes, compatible with expensive and/or poorly available drugs. Cationic SLN (cSLN) were produced using a commercial lipid matrix (Softisan® S100), loaded with a lipophilic probe compound. These cationic carriers could be advantageous in ensuring a prolonged retention onto the negatively charged mucous surface of the cornea. Depending on their composition, cSLN systems with a mean size around 170-250 nm, a good size distribution profile, and a net positive charge (+30/+50 mV) were produced by the QESD technique. Only highly biocompatible, ICH-class 3 solvents, such as ethanol and acetone, were used. Most nanocarriers showed a good physical stability upon storage and could be produced respecting some formulation requirements, such as pH close to neutrality and an osmolarity compatible with the eye surface.

Optimization and Validation of a New Method for the Production of Lipid Nanoparticles for Ophthalmic Application